HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

D-JNKI-1

a synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of oxidative stress

Also Known As:

AM 111; AM-111; AM111 peptide; XG 102; XG-102; XG102 peptide

Networked: 17 relevant articles (0 outcomes, 4 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 16238
  - D-JNKI-1: 17

Experts

1.	Bonny, Christophe: 6 articles (01/2008 - 03/2006)
2.	Ji, Ru-Rong: 4 articles (02/2010 - 03/2006)
3.	Xu, Zhen-Zhong: 3 articles (02/2010 - 04/2009)
4.	Gao, Yong-Jing: 3 articles (02/2010 - 04/2009)
5.	Decosterd, Isabelle: 3 articles (02/2010 - 03/2006)
6.	Wen, Yeong-Ray: 2 articles (02/2010 - 03/2006)
7.	Borsello, Tiziana: 2 articles (11/2009 - 03/2006)
8.	Meyer, Thomas: 2 articles (12/2007 - 04/2007)
9.	Zine, Azel: 2 articles (04/2007 - 06/2006)
10.	Wang, Jing: 2 articles (04/2007 - 03/2007)

Related Diseases

1.	Hearing Loss (Hearing Impairment) 01/01/2010 - "CONCLUSIONS: AM-111 prevents hearing loss from SC transection in the guinea pig model of PA-OM." 01/01/2010 - "The goal of this study was to determine if round window application of AM-111 following SC transection in the presence of Pseudomonas aeruginosa otitis media (PA-OM) may reduce the associated hearing loss. " 01/01/2010 - "AM-111, an apoptosis inhibitor, has been shown to mitigate hearing loss resulting from a variety of inner ear injuries. " 01/01/2010 - "AM-111 prevents hearing loss from semicircular canal injury in otitis media." 12/01/2007 - "AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis." Order ALL the reference details at left...
2.	Inflammation 02/01/2010 - "Intrathecal infusion of a selective peptide inhibitor of JNK, D-JNKI-1, starting before inflammation via an osmotic pump, reduced CFA-induced mechanical allodynia in the maintenance phase but had no effect on CFA-induced heat hyperalgesia. " 12/01/2007 - "OBJECTIVES/HYPOTHESIS: This study investigated the otoprotective properties of AM-111, an inhibitor of c-Jun N-terminal kinase-mediated apoptosis and inflammation. " Order ALL the reference details at left...
3.	Noise-Induced Hearing Loss (Acoustic Trauma) 09/01/2007 - "SUBJECTS AND METHODS: For the first application of AM-111 in humans, we organized a clinical phase I/II trial in patients with acute acoustic trauma after exposure to firecrackers in Berlin and Munich on New Year's Eve 2005/2006. " 09/17/2003 - "Local delivery of D-JNKI-1 also prevented acoustic trauma-induced permanent hearing loss in a dose-dependent manner. " Order ALL the reference details at left...
4.	Otitis Media 01/01/2010 - "The goal of this study was to determine if round window application of AM-111 following SC transection in the presence of Pseudomonas aeruginosa otitis media (PA-OM) may reduce the associated hearing loss. " 01/01/2010 - "AM-111 prevents hearing loss from semicircular canal injury in otitis media." Order ALL the reference details at left...
5.	Wounds and Injuries (Trauma) 04/01/2007 - "The otoprotective peptide AM-111, a cell-permeable inhibitor of JNK mediated apoptosis, was tested for its efficacy as a rescue agent following impulse noise trauma. " 03/01/2007 - "Blocking this signaling pathway with RWM delivery of d-JNKI-1 may have significant therapeutic value as a therapeutic intervention to protect the human cochlea from the effects of sound trauma." 03/01/2007 - "The therapeutic window for protection of the cochlea from sound trauma with RWM delivery of d-JNKI-1 extended out to 12 h after sound exposure. " 03/01/2007 - "In addition to blocking JNK-mediated activation of a mitochondrial cell death pathway, RWM-delivered d-JNKI-1 prevents hair cell death and development of a permanent shift in hearing threshold that is caused by sound trauma in a dose-dependent manner (EC50 = 2.05 microM). " 01/01/2010 - "AM-111, an apoptosis inhibitor, has been shown to mitigate hearing loss resulting from a variety of inner ear injuries. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	JNK Mitogen-Activated Protein Kinases
2.	Neomycin
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Oxygen
5.	Hyaluronic Acid (Hyaluronan)
6.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Cochlear Implantation
2.	Resuscitation
3.	Ligation
4.	Intravenous Injections
5.	Injections

blog comments powered by Disqus

TREATMENT OPTIONS
for Hearing Loss,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 178 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>